- Home
- EVRG vs ILMN Comparison
EVRG vs ILMN Comparison
Compare EVRG & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVRG | ILMN |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9B | 18.9B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | EVRG | ILMN |
|---|---|---|
| Price | $74.55 | $129.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 15 |
| Target Price | $78.35 | ★ $114.93 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 3.66 | ★ 4.46 |
| Revenue | ★ $5,878,800,000.00 | $4,288,000,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $3.76 | $2.22 |
| P/E Ratio | ★ $20.44 | $28.65 |
| Revenue Growth | ★ 1.75 | N/A |
| 52 Week Low | $59.67 | $68.70 |
| 52 Week High | $79.32 | $153.06 |
Technical Indicators
Market Signals| Indicator | EVRG | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 66.85 |
| Support Level | $74.90 | $127.43 |
| Resistance Level | $77.63 | $132.15 |
| Average True Range (ATR) | 1.13 | 4.14 |
| MACD | -0.23 | -0.13 |
| Stochastic Oscillator | 13.30 | 80.27 |
Price Performance
Historical ComparisonAbout EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission Co. The utility has a combined rate base of approximately $20 billion, about half in Kansas and the rest split between Missouri and federal jurisdiction. Evergy is one of the largest wind energy suppliers in the US.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.